Streamlining Transatlantic Apheresis Access for Cell & Gene Therapy Developers
CGT Global and SCTbio have joined forces to improve the future of cell and gene therapy by strengthening apheresis networks and enhancing the scalability of therapy manufacturing and patient access across the US and Europe.
A Smarter Path for Global Trials
Bringing together decades of experience and a combined network of over 150 global apheresis sites and state-of-the-art laboratories, the two organizations are collaborating to streamline every step of the therapeutic development lifecycle – from early-stage research to full commercialization on a global basis.
Together, CGT Global and SCTbio offer:
Global Access:
Clients working with either organization can access the combined network, reducing cross-region setup time and operational complexities
Protocol alignment
Standardized collection approaches to ensure consistency across US and EU sites enabling cost-savings and efficiencies of scale
Coordinated logistics:
Simplified material transfer, logistics and scheduling across global networks
Reduced qualification burden:
Leveraging existing audits and quality standards to accelerate site readiness
Experienced GMP Manufacturing Teams:
Expertise in vector production and CGT manufacturing and cell isolation
Global Support, End-to-End: Supporting clients through clinical development to commercial readiness with high-quality standards maintained throughout the process.
Why This Collaboration Matters
“This collaboration represents a significant step forward for the industry and for global access to life-saving therapies. Together with SCTbio, we’re not just accelerating therapies – we are expanding global access. Our complementary strengths allow us to deliver transformative therapies to patients faster, more efficiently, and on a global scale.”
— Cate Spears, Founder & CEO, CGT Global
“We are proud to partner with CGT Global to expand access to life-saving cell and gene therapies. At SCTbio, we have built one of Europe’s most experienced GMP manufacturing teams and a robust apheresis network supporting therapy developers worldwide. Together, with our expertise in lentiviral and gamma-retroviral vector production, best-in-class logistics, and globally competitive solutions, we are accelerating the delivery of transformative therapies to patients safely, efficiently, and at scale.”
— Luděk Sojka, CEO, SCTbio
About the Partners
For nearly two decades, CGT Global has redefined what is possible in the biotechnology landscape by accelerating clinical research, drug discovery, translational science, clinical trials, and the development of innovative therapies by accelerating research, streamlining clinical trials and supporting the commercialization of new cell and gene therapies. With their national U.S. footprint and expanding global reach, CGT Global offers GMP-compliant and RUO materials, clinical trial support, and is developing the future of outpatient care for cell therapy patients. Headquartered in Folsom, CA, CGT Global partners with top pharmaceutical companies, CROs, and hospitals.
SCTbio is a leading European CDMO specializing in advanced therapy medicinal products (ATMPs). With over 15 years of cell therapy manufacturing experience, SCTbio provides end-to-end GMP services — from apheresis materials, vector production, and process development to manufacturing, quality control, release, storage, and logistics. Backed by a highly skilled team and an extensive European apheresis network, the company ensures flexibility, continuity, and globally competitive pricing. As part of the PPF Biotech group, SCTbio partners with clients from clinical development through commercial readiness, maintaining the highest quality standards throughout.
Ready to Expand Your Trial Across the Atlantic?
Let’s simplify your path to global success.
Our unique combined services include:
- Coordination of apheresis products in multiple regions across the globe
- Lentiviral and gamma-retroviral vector production
- GMP fresh and frozen leukopaks and isolated cells
- Mobilized leukopaks
- Diseased state leukopaks for global shipments
- CAR-T manufacturing
- Customized GMP Cell isolations
- And more -- tell us about your project